The Case of the Missing Patients
China is finally looking into its scientists’ human gene-editing trials — but some patients are already out of view.
According a newly published Wall Street Journal story, Chinese scientists using CRISPR technology provided by the startup Anhui Kedgene Biotechnology have lost touch with at least some of the late-stage cancer patients whose DNA they altered.
That means no one knows for sure how the editing may have affected the patients in the longer term — and according to experts, that lack of follow-up could affect CRISPR research far beyond China’s borders.
In the U.S., the Food and Drug Administration recommends that researchers follow up with patients involved in gene therapy trials for 15 years. No such recommendation exists in China, however, and Chinese CRISPR researchers’ lack of extended follow-up could prove disastrous as the nascent technology finds its footing.
Feng Zhang, one of the inventors of CRISPR, told The WSJ that gene-editing trials “hinge upon rigorous trial design and follow-ups.” Jennifer Doudna, another CRISPR inventor, said it’s “vital” that researchers conduct long-term monitoring of gene-edited patients.
“Since we do not fully understand the human genome and are still developing knowledge of CRISPR-Cas technology, we need to monitor the intended and unintended consequences over the lifespan of patients,” Doudna told The WSJ.
The Chinese government has thus far remained fairly hands-off with regards to CRISPR research — it hasn’t even tasked any one federal body with overseeing its gene-editing trials — but that could be changing.
On Thursday, the South China Morning Post reported that China is asking hospitals and universities to submit thorough reports on all human gene-editing trials conducted since 2013.